CAR T studies highlight Abramson Cancer Center research at ASH Annual Meeting

From better-understanding how to improve response rates in multiple myeloma patients to identifying why some patients with other types of cancer are resistant in the first place, research from the Abramson Cancer Center of the University of Pennsylvania continues to pace the field in expanding knowledge of cellular therapies for cancer care. Penn researchers will present findings at the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, including studies that evaluate CAR T combinations, how the timing of CAR T therapy may impact its effectiveness, and which patients who currently aren’t eligible for CAR T therapy should have greater access. Here’s a day-by-day breakdown of the Abramson Cancer Center’s CAR T research highlights:

Read more at: https://www.eurekalert.org/pub_releases/2018-11/uops-cts112618.php